Focus On The Core: Merck Claims R&D Restructuring Poised To Produce Results
Executive Summary
At an R&D day presentation in Boston, Merck executives claimed R&D restructuring is beginning to bear fruit, presenting the pharma with a host of near-term launch possibilities. Outside of cancer immunotherapy, Merck has obtained or anticipates approvals in cardiovascular health, insomnia, diabetes, hepatitis C, osteoporosis, and allergies.
You may also be interested in...
Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself
Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.
Merck Bets Big On Oncology In New R&D Strategy
The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks to Generics Bulletin about how the firm is gearing up to launch three key products.